All Terrain Financial Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 21.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,104 shares of the company’s stock after selling 567 shares during the quarter. All Terrain Financial Advisors LLC’s holdings in Johnson & Johnson were worth $296,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. Sofos Investments Inc. boosted its position in shares of Johnson & Johnson by 172.0% in the 1st quarter. Sofos Investments Inc. now owns 1,148 shares of the company’s stock worth $33,000 after purchasing an additional 726 shares in the last quarter. Altshuler Shaham Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at approximately $35,000. Lake Point Wealth Management lifted its position in Johnson & Johnson by 144.4% in the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after acquiring an additional 169 shares in the last quarter. Lion Street Advisors LLC bought a new position in Johnson & Johnson in the 1st quarter valued at approximately $45,000. Finally, SeaBridge Investment Advisors LLC lifted its position in Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares in the last quarter. 68.44% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the sale, the executive vice president now directly owns 21,682 shares in the company, valued at approximately $3,197,444.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.27% of the company’s stock.
NYSE:JNJ opened at $145.76 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 1.05. The firm has a market capitalization of $383.76 billion, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 3.23 and a beta of 0.69. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The business has a fifty day moving average price of $144.04 and a 200-day moving average price of $144.14.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. Johnson & Johnson’s revenue was down 10.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.58 EPS. On average, equities research analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
JNJ has been the topic of several analyst reports. Morgan Stanley upped their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Citigroup upped their price objective on Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Friday, July 17th. UBS Group cut Johnson & Johnson from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $163.00 to $160.00 in a research report on Tuesday, April 28th. Raymond James upped their price objective on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Finally, Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the company from $161.00 to $164.00 in a research note on Monday, July 20th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $163.38.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a portfolio manager?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.